期刊
NATURE COMMUNICATIONS
卷 12, 期 1, 页码 -出版社
NATURE PORTFOLIO
DOI: 10.1038/s41467-021-22531-3
关键词
-
资金
- CRUK Career Development Fellowship [A19166]
- ERC Starting Grant [715782, 311301]
- CRUK grants [A26825, A28233, A23390, A21139, A12481, A17196]
- Clinical Scientist Fellowships from CRUK [C26031/A11378]
- Chief Scientist Office [SCAF/16/01]
- Wellcome Trust [208402/Z/17/Z]
- European Research Council (ERC) [311301, 715782] Funding Source: European Research Council (ERC)
Current therapeutic options for colorectal cancer are limited in efficacy, often resulting in acquired resistance during treatment. Research has identified RAC1B as a key mediator of colorectal tumourigenesis and a potential target for enhancing EGFR inhibitor treatment. Inhibition of RAC1B has been shown to sensitize cetuximab-resistant colorectal cancer cells to EGFR inhibitors, presenting a promising therapeutic target for improving clinical efficacy.
Current therapeutic options for treating colorectal cancer have little clinical efficacy and acquired resistance during treatment is common, even following patient stratification. Understanding the mechanisms that promote therapy resistance may lead to the development of novel therapeutic options that complement existing treatments and improve patient outcome. Here, we identify RAC1B as an important mediator of colorectal tumourigenesis and a potential target for enhancing the efficacy of EGFR inhibitor treatment. We find that high RAC1B expression in human colorectal cancer is associated with aggressive disease and poor prognosis and deletion of Rac1b in a mouse colorectal cancer model reduces tumourigenesis. We demonstrate that RAC1B interacts with, and is required for efficient activation of the EGFR signalling pathway. Moreover, RAC1B inhibition sensitises cetuximab resistant human tumour organoids to the effects of EGFR inhibition, outlining a potential therapeutic target for improving the clinical efficacy of EGFR inhibitors in colorectal cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据